Apomorphine Hydrochloride (Sumitomo Pharma America)

N/A

Report date: 2024/04/26 20:00:28

Base Information

Drug NameApomorphine Hydrochloride (Sumitomo Pharma America)
Drug Alias NameApomorphine HCI (Sumitomo Pharma America)Apomorphine HCI sublingual film (Sumitomo Pharma America)Apomorphine Hydrochloride Sublingual Thin Film (Sumitomo Pharma America)Apomorphine Hydrochloride, Sublingual Thin Film (Sumitomo Pharma America)Apomorphine sublingual film (Sumitomo Pharma America) +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonists
TargetsDopamine receptors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/05/21
Country/TerritoryCanadaUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesInvivyd Inc
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Pharma America Inc
Inactive CompaniesSunovion Pharmaceuticals Inc
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A